...although it sure feels like this wants to go lower. I'd add a bunch if ACTS goes to around $2.20 or so.
Quarter was about as expected. Guidance was pretty good...revenue growth will continue. And they did say in the Conf Call that R&D will revert back to normal levels after the $1.4 million or so uptick in the June quarter. Of course normal is still super high, but at least it goes back to normal levels going forward.